MDMAT (6,7-methylenedioxy-N-methyl-2-aminotetralin) is a selective serotonin releasing agent (SSRA) and entactogen drug. It is the N-methylatedderivative of MDAT, similarly to the relationship of MDMA to MDA.[2][3] It has been theorized to have less long-term neurotoxicity and less hallucinogenic effects than other MDxx derivatives,[4] but no formal scientific research has been conducted specifically on MDMAT.
There is a lack of research on MDMAT in general, with much of the research and citation in literature being in reference to the wider pharmalogical/chemical class as a whole.
Chemistry
MDMAT is a substituted methylenedioxyphenethylamine, having structural similarities to MDMA and MDA.
^Violland R, Violland-Duperret N, Pacheco H, Trouiller G, Lebland A (1971). "Potential psychotropic compounds. VIII. Synthesis and pharmacological activity of 2-aminotetralins related to psychomimetics". Chimica Therapeutica. 6 (3): 196.
^Malmusi L, Dukat M, Young R, Teitler M, Darmani NA, Ahmad B, et al. (January 1996). "1,2,3,4-Tetrahydroisoquinoline and related analogs of the phenylalkylamine designer drug MDMA". Medicinal Chemistry Research. 6 (6): 412–26m.
^Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM (February 1990). "Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry. 33 (2): 703–710. doi:10.1021/jm00164a037. PMID1967651.
